Antimicrobial resistance (AMR) is an arms race between humans and bacteria that is being lost. By 2050, 10 million AMR deaths and US$100t in economic losses are expected per annum. AMR is driven by antibiotic or biocide overuse, pollution and an innovation machinery that repeats the same tactics, expecting different results.
Lixa is developing non-antibiotic, universal resistance breakers that restore the efficacy of first-line antibiotics to below clinical break-point, even in resistant and biofilm-protected bacteria. Lixa’s NeoXTM molecules have the hallmarks of a promising AMR solution due to broad scalability across jurisdictions, climates, resistance mechanisms and bacterial species as well as cost-effectiveness and solubility. NeoX™ is compatible with existing antimicrobials (including antibiotics and antifoul agents) and applicable across human health, agribusiness and industrial markets.
Learn more on the Lixa website.
